Purified anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse CTL clone V4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography.

Concentration

0.5 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C.

Application

FC - Quality tested
IHC-F, IP - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
2. Liao X, et al. 2022. Front Immunol. 12:768813. PubMed
3. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
4. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
5. Chami B, et al. 2017. Sci Rep. 7:10181. PubMed
6. Tsukumo S, et al. 2006. J Immunol. 177:8365. PubMed
7. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
8. Fernandes V, et al. 2020. PLoS Pathog. 16:e1008464. PubMed
9. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
10. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
11. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
12. Hummel JF, et al. 2020. Mucosal Immunol. 0.720138889. PubMed
13. Smith CJ, et al. 2018. J Immunol. 200:1580. PubMed
14. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
15. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
16. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
17. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
18. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
19. Shirakawa K, et al. 2017. PLoS One. 12:e0186303. PubMed
20. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
21. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
22. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
23. Duvvuri M, et al. 2019. Biomater Sci. 7:1863. PubMed
24. Hashimoto K, et al. 2021. J Dermatol Sci. 102:177. PubMed
25. Haque M, et al. 2021. Viruses. 13:. PubMed
26. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
27. Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed
28. Hirano J, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
29. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
30. Rossi DC, et al. 2021. J Clin Invest. 131:. PubMed
31. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
32. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
33. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
34. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
35. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
36. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
37. Xie MM, et al. 2017. Eur J Immunol. 47:1136. PubMed
38. Zhou AC, et al. 2017. Front Immunol. 1.136111111. PubMed
39. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
40. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
41. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
42. Lasrado N, et al. 2021. Microorganisms. 9:. PubMed
43. Tan L, et al. 2017. Int J Nanomedicine. 12:3095. PubMed
44. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
45. Wang N, et al. 2021. Mol Ther Oncolytics. 20:71. PubMed
46. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
47. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
48. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
49. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
50. Sharma M, et al. 2020. Nat Commun. 11:661. PubMed
51. Skeate JG, et al. 2018. PLoS One. 13:e0191311. PubMed
52. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
53. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
54. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
55. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
56. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
57. Shokirova H, et al. 2021. Sci Rep. 11:8647. PubMed
58. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
59. Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed
60. Elsayed H, et al. 2018. J Virol. 92:e00428. PubMed
61. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
62. Hu M, et al. 2008. J Immunol. 180:6593. PubMed
63. Hsiao CC, et al. 2021. Cells. 10:. PubMed
64. Horiuchi S, et al. 2021. Sci Immunol. :eabm3131. PubMed
65. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
66. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
67. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
68. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
69. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
70. Pierini A, et al. 2017. JCI Insight. 2. PubMed
71. Sprouse ML, et al. 2018. JCI Insight. 3:e97322. PubMed
72. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
73. Liu M, et al. 2018. Diabetologia. 61:2333. PubMed
74. Sharabi A, et al. 2019. JCI Insight. 4:e126294. PubMed
75. Majer O, et al. 2019. Nature. 575:366. PubMed
76. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
77. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
78. Zelazowska MA, et al. 2020. Life Sci Alliance. :3. PubMed
79. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
80. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
81. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
82. Zhang H, et al. 2017. J Immunol. 198:2133. PubMed
83. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
84. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
85. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
86. Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed
87. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
88. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
89. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
90. Chen X, et al. 2019. Methods Mol Biol. 2048:131. PubMed
91. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
92. Meyers JL, et al. 2018. PLoS One. 13:e0207007. PubMed
93. Floudas A, et al. 2017. J Immunol. 199:707. PubMed
94. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
95. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
96. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
97. Pradhan P, et al. 2017. JCI Insight. 2. PubMed
98. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
99. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
100. Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed
101. Wilhelmson AS, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1519. PubMed
102. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
103. Stefanski HE, et al. 2018. PLoS One. 13:e0198871. PubMed
104. Liu J, et al. 2022. Stem Cell Res Ther. 13:247. PubMed
105. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
106. Zhang Z, et al. 2020. Front Immunol. 1.844444444. PubMed
107. Rosenberg J, et al. 2020. Cell Systems. 10(5):433-444. PubMed
108. Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed
109. Dey P, et al. 2020. Cancer Discov. 10:608. PubMed
110. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
111. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
112. Luu M, et al. 2019. Nat Commun. 10:760. PubMed
113. Di Dalmazi G, et al. 2019. J Immunol. 202:1350. PubMed
114. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
115. Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed
116. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
117. Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed
118. Zhang N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
119. Whittle JR, et al. 2020. Clin Cancer Res. 26:4120. PubMed
120. Liu H, et al. 2022. Animal Model Exp Med. 5:72. PubMed
121. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
122. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
123. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
124. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
125. Krämer TJ, et al. 2019. J Neuroinflammation. 16:163. PubMed
126. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
127. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed

RRID

AB_312686 (BioLegend Cat. No. 100401)
AB_312687 (BioLegend Cat. No. 100402)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis